STOCK TITAN

Xeris Biopharma Holdings - XERS STOCK NEWS

Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.

Xeris Biopharma Holdings Inc (XERS) is a biopharmaceutical innovator developing ready-to-use therapies for complex conditions in endocrinology, neurology, and gastroenterology. This page aggregates official company announcements, regulatory milestones, and research developments for stakeholders tracking its progress.

Access timely updates on XERS' FDA-approved products including Gvoke (severe hypoglycemia), Recorlev (Cushing's Syndrome), and proprietary formulation platforms like XeriSol and XeriJect. Our curated news feed covers clinical trial results, partnership announcements, manufacturing updates, and financial disclosures essential for understanding the company's trajectory in advanced biotherapeutics.

This resource serves investors and healthcare professionals needing verified information about XERS' patient-centric solutions. Content is organized chronologically with clear sourcing to facilitate efficient research. Bookmark this page for structured access to earnings reports, regulatory filings, and scientific advancements from one of biopharma's most innovative formulation specialists.

Rhea-AI Summary

Xeris Pharmaceuticals (Nasdaq: XERS) announces a significant milestone for Gvoke, a ready-to-use glucagon treatment for severe hypoglycemia, achieving extensive payor coverage. Approximately 91% of Medicare patients and 88% of commercially insured patients now have unrestricted access to Gvoke. The company emphasizes its commitment to affordable healthcare and effective market access strategies. The press release highlights the importance of ensuring access for patients, especially with children returning to school. Gvoke was FDA-approved in September 2019, and it is crucial for diabetes management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
none
-
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced the FDA's approval of its Investigational New Drug Application (IND) for XeriSol levothyroxine, enabling the initiation of a Phase 1 clinical study for XP-8121. This study will assess the pharmacokinetics, safety, and tolerability of XeriSol's subcutaneous levothyroxine treatment for hypothyroidism. The company aims to address unmet needs in oral levothyroxine therapy by offering weekly subcutaneous injections to improve patient compliance and mitigate existing treatment challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
none
-
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced its Q2 financial results for 2021, showcasing a 32% increase in Gvoke net sales, totaling $8.8 million. The company reported a net loss of $27.5 million, improving from a loss of $24.1 million in Q2 2020. The proposed acquisition of Strongbridge Biopharma is anticipated to close in Q4 2021, with a cash position of $116 million. Gvoke's prescription volume surged, reaching over 21,000, and a partnership with Tetris Pharma aims to commercialize Ogluo in Europe, potentially adding up to $71 million in future payments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.98%
Tags
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) reported its issued share capital as of July 28, 2021, consisting of 66,497,370 shares of common stock. The company also noted 5,081,323 stock options, 2,059,762 restricted stock units, 94,012 warrants, and $47,175,000 in convertible notes due 2025. Xeris, known for its innovative injectable therapeutic solutions, has technologies that improve the ease and stability of drug administration, including its commercial product, Gvoke®. The announcement also highlights upcoming SEC filings related to the acquisition of Strongbridge Biopharma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
none
-
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) will release its second quarter 2021 financial results on August 5, 2021, before the U.S. market opens. A conference call will be held at 8:30 a.m. ET to discuss financial and operational results. Xeris specializes in ready-to-use injectable formulations, with its proprietary technologies such as XeriSol™ and XeriJect™, aimed at simplifying administration and enhancing stability. The company's first commercial product is Gvoke®. Investors can register for the call and access a replay later.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
-
Rhea-AI Summary

Xeris Pharmaceuticals (Nasdaq: XERS) announced executive changes to strengthen its commercial strategy, particularly ahead of the acquisition of Strongbridge Biopharma. CFO Barry Deutsch has stepped down but will assist during the transition until the merger's expected completion in Q4 2021. Steven Pieper, with 20 years of healthcare finance experience, has been promoted to CFO. He previously helped launch Xeris's first commercial product, Gvoke®. The company continues to focus on innovative, ready-to-use injectable drug formulations to enhance patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
none
Rhea-AI Summary

Xeris Pharmaceuticals (Nasdaq: XERS) has entered an exclusive agreement with Tetris Pharma for the commercialization of Ogluo® in the European Economic Area, the UK, and Switzerland, aimed at treating severe hypoglycaemia in diabetes patients. Xeris is set to receive up to $71 million in milestone payments and royalties on net sales. The partnership is expected to enhance Ogluo's accessibility to insulin-dependent diabetes patients, where the demand is significant, yet current glucagon prescriptions remain low.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
-
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) disclosed that on July 1, 2021, it granted 80,250 restricted stock units to 37 new employees through its Inducement Equity Plan. This plan targets new hires as incentives for accepting employment. The stock options will vest over four years, with various vesting schedules based on employment duration. Xeris specializes in ready-to-use injectable formulations, aiming to simplify medication delivery and reduce healthcare costs. Its proprietary technologies, XeriSol™ and XeriJect™, enhance stability and ease of use for patients and providers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.29%
Tags
none
-
Rhea-AI Summary

Xeris Pharmaceuticals (XERS) has announced an agreement to acquire Strongbridge Biopharma (SBBP) for approximately $267 million in stock and contingent value rights (CVRs). Strongbridge shareholders will receive a fixed exchange ratio of 0.7840 shares of the new entity, Xeris Biopharma Holdings, and potential CVRs based on sales milestones of KEVEYIS® and RECORLEV®. This merger aims to create a diversified biopharmaceutical company focused on rare diseases, enhancing revenue growth with commercial assets like Gvoke® and RECORLEV®. The transaction is expected to close in Q4 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
Rhea-AI Summary

Xeris Pharmaceuticals (XERS) announced its acquisition of Strongbridge Biopharma (SBBP) for approximately $267 million, combining their operations into Xeris Biopharma Holdings. Strongbridge shareholders will receive 0.7840 shares of Xeris for each of their shares, translating to about $2.72 per share, a 12.9% premium. Contingent value rights (CVRs) could add up to $1.00 per share based on sales targets for KEVEYIS and RECORLEV. Post-acquisition, current Xeris shareholders will hold 60% of the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.76%
Tags
Xeris Biopharma Holdings

Nasdaq:XERS

XERS Rankings

XERS Stock Data

632.69M
147.65M
3.99%
42.87%
6.91%
Biotechnology
Pharmaceutical Preparations
Link
United States
CHICAGO